Corrigendum to “Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity” [Mol Metab 78 (2023) 101801]

• Martin Haljeta Friedrichsen,
• Lars Endahl,
• Frederik Flindt Kreiner,
• Ronald Goldwater,
• Martin Kankam,
• Søren Toubro,
• Sune Boris Nygård

Affiliations

Martin Haljeta Friedrichsen

Novo Nordisk A/S, Søborg, Denmark; Corresponding author. Dr Martin Haljeta Friedrichsen, Novo Nordisk A/S, Vandtårnsvej 108, Suborn, DK-2860, Denmark.

Lars Endahl

Novo Nordisk A/S, Søborg, Denmark

Frederik Flindt Kreiner

Novo Nordisk A/S, Søborg, Denmark

Ronald Goldwater

Parexel International, Baltimore, MD, USA

Martin Kankam

Altasciences Clinical Kansas, Overland Park, KS, USA

Søren Toubro

Novo Nordisk A/S, Søborg, Denmark

Sune Boris Nygård

Novo Nordisk A/S, Søborg, Denmark